Neuropathologic Involvement of the Dopaminergic Neuronal Systems in Parkinson's Disease

Parkinson's Disease: Non-Motor and Non-Dopaminergic Features

Volumn , Issue , 2011, Pages 7-14

  Perl, Daniel P ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

A10 dopamine neurons melanized neuron combination; Approach, correlation of distribution degree of brain neurodegeneration; Dahlstr m and Fuxe nomenclature identifying cell groups systematically; Dopaminergic neuronal group involvement in Parkinson's disease; Dopaminergic neuronal systems, and neuropathologic involvement in Parkinson's disease; Hypothalamic dopaminergic neurons (A13); Mesolimbic pathways, medial tier of midbrain dopaminergic neurons; SNc, heterogeneous components, specific striatal projections; Stereologic principles counting of SNc neurons, in normal aging controls; Substantia nigra pars compacta (SNc) grossly visible black substance in midbrain

Indexed keywords

EID: 84885504102     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444397970.ch2     Document Type: Chapter

References (43)

1. Dahlström A, Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. 1. Demonstration of monoamines in cell bodies of brainstem neurons. Acta Physiol Scand Suppl 1964;232:3-55.
2. Hassler R. Zur Neuroanatomie de Substantia Nigra. J Psychol Neurol 1937;48:1-55.
3. Olszewski J, Baxter D. Cytoarchitechture of the Human Brainstem. Philadelphia, PA: JB Lippincott, 1954.
4. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54(5):388-96.
5. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999;122(Pt 8):1421-36.
6. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopaminecontaining neurons in Parkinson's disease. Brain 1999;122(Pt 8): 1437-48.
7. McRitchie DA, Hardman CD, Halliday GM. Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J Comp Neurol 1996;364(1):121-50.
8. Spencer S, Saper CB, Joh T, et al. Distribution of catecholaminecontaining neurons in the normal human hypothalamus. Brain Res 1985;328(1):73-80.
9. Saper CB, Petito CK. Correspondence of melanin-pigmented neurons in human brain with A1-A14 catecholamine cell groups. Brain 1982;105(Pt 1):87-101.
10. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977;34(1):33-5.
11. Mann DM, Yates PO, Marcyniuk B. Monoaminergic neurotransmitter systems in presenile Alzheimer's disease and in senile dementia of Alzheimer type. Clin Neuropathol 1984;3(5): 199-205.
12. Thiessen B, Rajput AH, Laverty W, Desai H. Age, environments, and the number of substantia nigra neurons. Adv Neurol 1990;53:201-6.
13. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):283-301.
14. Kubis N, Faucheux BA, Ransmayr G, et al. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 2000;123(Pt 2):366-73.
15. West MJ. New stereological methods for counting neurons. Neurobiol Aging 1993;14:275-85.
16. Sterio DC. The unbiased estimation of number and size of arbitrary particles using the disector. J Microsc 1984;134:127-36.
17. Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B. Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 2002;28(4):283-91.
18. Chu Y, Kompoliti K, Cochran EJ, et al. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol 2002;450(3):203-14.
19. Ma SY, Roytt M, Collan Y, Rinne JO. Unbiasedmorphometrical measurements show loss of pigmented nigral neurones with ageing. Neuropathol Appl Neurobiol 1999;25(5):394-9.
20. Rudow G, O'Brien R, Savonenko AV, et al. Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol 2008;115(4):461-70.
21. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86.
22. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol (Berl) 1991;82:239-59.
23. Calne DB, Mizuno Y. The neuromythology of Parkinson's disease. Parkinsonism Relat Disord 2004;10(5):319-22.
24. Weiner WJ. There is no Parkinson disease. Arch Neurol 2008; 65(6):705-8.
25. Marsden CD. Parkinson's disease. Lancet 1990;335(8695): 948-52.
26. Snow BJ, Nygaard TG, Takahashi H, Calne DB. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann Neurol 1993;34(5): 733-8.
27. Hassler R. Zur Pathologie der Paralysis Agitans und des postencephalitischen Parkinsonismus. J Psychol Neurol 1938; 48:387-476.
28. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318(14):876-80.
29. van Domburg PHMF, ten Donkelaar HJ. The Human Substantia Nigra and Ventral Tegmental Area: a Neuroanatomical Study with Notes on Aging and Aging Diseases. Berlin: Springer, 1991.
30. Rinne JO, Rummukainen J, Paljarvi L, Rinne UK. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989;26(1):47-50.
31. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139(9):1136-9.
32. McRitchie DA, Cartwright HR, Halliday GM. Specific A10 dopaminergic nuclei in themidbrain degenerate in Parkinson's disease. Exp Neurol 1997;144(1):202-13.
33. McRitchie DA, Halliday GM, Cartwright H. Quantitative analysis of the variability of substantia nigra pigmented cell clusters in the human. Neuroscience 1995;68(2):539-51.
34. Björklund A, Lindvall O, Nobin A. Evidence of an incertohypothalamic dopamine neurone system in the rat. Brain Res 1975;89(1):29-42.
35. Felten DL, Laties AM, Carpenter MB. Monoamine-containing cell bodies in the squirrel monkey brain. Am J Anat 1974; 139(2):153-65.
36. Matzuk MM, Saper CB. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann Neurol 1985;18(5):552-5.
37. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
38. Halliday GM, Ophof A, Broe M, et al. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005;128(Pt 11):2654-64.
39. Ma SY, Roytta M, Rinne JO, et al. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci 1997; 151(1):83-7.
40. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334(6180):345-8.
41. Torta DM, Castelli L. Reward pathways in Parkinson's disease: clinical and theoretical implications. Psychiatry Clin Neurosci 2008;62(2):203-13.
42. Trétiakoff MC. Contribution a l'étude de l'Anatomie Pathologique de Locus Niger de Soemmerling. Université de Paris, 1919.
43. Foix C. Les lesions anatomiques de la maladie de Parkinson. Rev Neurol 1921;37:593-600.